TCGA-OR-A5KO-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.561
- G2M_CHECKPOINT+0.534
- MITOTIC_SPINDLE+0.351
- MYC_TARGETS_V1+0.187
- SPERMATOGENESIS+0.144
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.123
- UV_RESPONSE_DN+0.105
- PEROXISOME+0.104
- HEDGEHOG_SIGNALING+0.067
- GLYCOLYSIS+0.066
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.502
- INTERFERON_ALPHA_RESPONSE-0.497
- IL6_JAK_STAT3_SIGNALING-0.489
- ALLOGRAFT_REJECTION-0.468
- INFLAMMATORY_RESPONSE-0.389
- OXIDATIVE_PHOSPHORYLATION-0.350
- PANCREAS_BETA_CELLS-0.345
- KRAS_SIGNALING_UP-0.311
- PI3K_AKT_MTOR_SIGNALING-0.304
- MYC_TARGETS_V2-0.277
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518210 | — | E | 0.843 |
| 2 | de92b16c-4549-4025-9885-76c260c30cf7 | — | — | 0.828 |
| 3 | ERR2278878 | — | — | 0.797 |
| 4 | MBCProject_6127_T1_RNA | — | B | 0.795 |
| 5 | C3N-03222 | — | cohortA4 | 0.787 |
| 6 | 2c343b93-910c-4921-bc2b-f7fbfa4f1596 | — | — | 0.784 |
| 7 | SRR9879267 | — | cohortA1 | 0.779 |
| 8 | 74d58c33-0c42-47bc-a55b-f56835480fbe | — | — | 0.777 |
| 9 | s0122172 | — | — | 0.777 |
| 10 | ERR2208889 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.561 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.534 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.351 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.187 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.144 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.123 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.105 | Inavolisib | — uncovered |
| PEROXISOME | 0.104 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.067 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.066 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.051 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.049 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.044 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.044 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.033 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.025 | Temsirolimus | — uncovered |
| HYPOXIA | 0.018 | Idelalisib | — uncovered |